Print Friendly, PDF & Email



Source: TOI

 Context: GlaxoSmithKline (GSK) Pharma has announced the launch of the Shingrix vaccine in India for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above.

VaccineShingrix ( for prevention of shingles)
About shinglesShingle is a viral infection that causes a painful rash. It can occur anywhere in your body. Shingles are caused by the varicella-zoster virus — the same virus that causes chickenpox
PurposeTo prevent shingles and post-herpetic neuralgia in adults aged 50 years or more
Virus TargetVaricella zoster virus (VZV)
TypeIt is the world’s first non-live, recombinant subunit vaccine to be given intramuscularly in two doses.
Approved ByUS Food and Drug Administration and the European Commission
Risk GroupsIndividuals with weakened immunity due to diabetes, heart disease, kidney diseases, etc.
What is a “non-live, recombinant subunit vaccine”?It is a type of vaccine that is made by taking a small piece of the germ (and not the whole germ) that causes a disease and using it to stimulate the body’s immune system to produce a response.